Scolaris Content Display Scolaris Content Display

Cirugía de mama por cáncer de mama metastásico

Appendices

Appendix 1. CENTRAL search strategy

#1 MeSH descriptor: [Breast Neoplasms] explode all trees

#2 (advanced breast cancer* or advanced breast neoplas* or advanced breast tumour* or advanced breast tumor*):ti,ab,kw

#3 (metastatic breast cancer* or metastatic breast neoplas* or metastatic breast tumour* or metastatic breast tumor*):ti,ab,kw

#4 #1 and (#2 or #3)

#5 MeSH descriptor: [Mastectomy] explode all trees

#6 MeSH descriptor: [Mastectomy, Radical] explode all trees

#7 MeSH descriptor: [Mastectomy, Segmental] explode all trees

#8 MeSH descriptor: [Mastectomy, Simple] explode all trees

#9 MeSH descriptor: [Mastectomy, Subcutaneous] explode all trees

#10 (Mastectom* or Segmentectom* or partial mastectom* or limited resection mastectom* or Lumpectom* or Local Excision Mastectom* or breast‐conserving surger* or Extended Radical Mastectom*):ti,ab,kw

#11 #5 or #6 or #7 or #8 or #9 or #10

#12 #4 and #11

Search updates (24 Ferbruary 2016)

#1 MeSH descriptor: [Breast Neoplasms] explode all trees
#2 breast near cancer*
#3 breast near neoplasm*
#4 breast near carcinoma*
#5 breast near tumour*
#6 breast near tumor*
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 #7 and (advance* or metasta* or stage IV or stage 4 or stage four)
#9 ("advanced breast cancer*" or "advanced breast neoplas*" or "advanced breast tumour*" or "advanced breast tumor*"):ti,ab,kw
#10 ("metastatic breast cancer*" or "metastatic breast neoplas*" or "metastatic breast tumour*" or "metastatic breast tumor*"):ti,ab,kw
#11 #8 or #9 or #10
#12 MeSH descriptor: [Mastectomy] explode all trees
#13 MeSH descriptor: [Mastectomy, Radical] explode all trees
#14 MeSH descriptor: [Mastectomy, Segmental] explode all trees
#15 MeSH descriptor: [Mastectomy, Simple] explode all trees
#16 MeSH descriptor: [Mastectomy, Subcutaneous] explode all trees
#17 (Mastectom* or Segmentectom* or Lumpectom*):ti,ab,kw
#18 "breast surger*":ti,ab,kw
#19 "breast resection":ti,ab,kw
#20 "breast amputation":ti,ab,kw
#21 "breast‐conserving surger*":ti,ab,kw
#22 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 #11 and #22

Appendix 2. MEDLINE search strategy

1. randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]

2. (((Breast neoplasms[mh] OR ((breast[mh] OR breast diseases[mh]) AND neoplasms[mh])) AND humans[mh]) OR DCIS[tiab] OR LCIS[tiab] OR ductal carcinoma in situ[tiab] OR lobular carcinoma in situ[tiab] OR (breast[tiab] AND (ductal carcinoma*[ti] OR lobular carcinoma*[ti])) OR ((Breast[ti] OR mammary[ti]) AND (cancer*[ti] OR neoplas*[ti] OR tumor*[ti] OR tumour*[ti] OR carcinoma*[ti] OR malignan*[ti] OR sarcoma[ti] OR lymphoma[ti]))) AND (Neoplasm Metastasis[Mh] OR secondary[sh] OR Neoplasm Recurrence, Local[mh] OR metast*[tiab] OR advanced[tiab] OR recurren*[tiab] OR HER‐2*[tiab] OR HER2*[tiab] OR N1[tiab] OR N2[tiab] OR N2a[tiab] OR N2b[tiab] OR N3[tiab] OR N3a[tiab] OR N3b[tiab] OR N3c[tiab] OR M1[tiab] OR pN1*[tiab] OR pN2*[tiab] OR pN3*[tiab] OR stage IV[tiab] OR stage four[tiab] OR stage 4[tiab] OR local*[tiab] OR loco*[tiab] OR region*[tiab] OR LABC[tiab] OR T3[tiab] OR T4[tiab] OR Stage III*[tiab] OR Stage three*[tiab] OR stage 3*[tiab])

3. (“Mastectomy” [Mesh]) OR (Mastectomies) OR (Mammectomy) OR (Mammectomies) OR (Mastectomies, Segmental) OR (Segmental Mastectomies) OR (Segmental Mastectomy) OR (Segmentectomy) OR (Segmentectomies) OR (Partial Mastectomy) OR (Mastectomies, Partial) OR (Mastectomy, Partial) OR (Partial Mastectomies) OR (Limited Resection Mastectomy) OR (Limited Resection Mastectomies) OR (Mastectomies, Limited Resection) OR (Mastectomy, Limited Resection) OR (Resection Mastectomies, Limited) OR (Resection Mastectomy, Limited) OR (Lumpectomy) OR (Local Excision Mastectomy) OR (Excision Mastectomies, Local) OR (Excision Mastectomy, Local) OR (Local Excision Mastectomies) OR (Mastectomies, Local Excision) OR (Mastectomy, Local Excision) OR (Breast‐Conserving Surgery) OR (Breast Conserving Surgery) OR (Breast‐Conserving Surgeries) OR (Surgeries, Breast‐Conserving) OR (Surgery, Breast‐Conserving) OR (Surgery, Breast Conserving) OR (Extended Radical Mastectomies) OR (Extended Radical Mastectomy) OR (Mastectomies, Extended Radical) OR (Radical Mastectomies, Extended) OR (Radical Mastectomy, Extended)

4. #1 AND #2 AND #3

5. #4 NOT (animals [mh] NOT humans [mh])

Appendix 3. Embase search strategy

  1. random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR (doubl* AND blind*) OR (singl* AND blind*) OR assign* OR allocat* OR volunteer*OR 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp OR 'single blind procedure'/exp

  2. 'advanced breast cancer'/exp OR 'advanced breast cancer'

  3. 'advanced breast carcinoma'

  4. 'advanced breast neoplasm'

  5. 'advanced breast tumour'

  6. 'advanced breast tumor'

  7. 'metastatic breast cancer'/exp OR 'metastatic breast cancer'

  8. 'metastatic breast carcinoma'

  9. 'metastatic breast neoplasm'

  10. 'metastatic breast tumour'

  11. 'metastatic breast tumor'

  12. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11

  13. 'breast surgery'/exp OR 'breast surgery'

  14. 'mastectomy'/exp OR 'mastectomy'

  15. 'partial mastectomy'/exp OR 'partial mastectomy'

  16. 'breast conserving surgery'/exp OR 'breast conserving surgery'

  17. 'breast sparing surgery'/exp OR 'breast sparing surgery'

  18. 'lumpectomy'/exp OR lumpectomy

  19. 'partial breast resection'/exp OR 'partial breast resection'

  20. 'breast amputation'/exp OR 'breast amputation'

  21. 'breast resection'/exp OR 'breast resection'

  22. 'extended radical mastectomy'

  23. 'modified radical mastectomy'

  24. 'simple mastectomy'

  25. 'radical mastectomy'/exp OR 'radical mastectomy'

  26. 'total mastectomy'/exp OR 'total mastectomy'

  27. #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26

  28. #1 AND #12 AND #27

  29. #28 NOT ([animals]/lim NOT [humans]/lim)

  30. #29 AND [embase]/lim

Appendix 4. Embase (via OvidSP) search strategy

1

Randomized controlled trial/

2

Controlled clinical study/

3

Random$.ti,ab.

4

randomization/

5

intermethod comparison/

6

placebo.ti,ab.

7

(compare or compared or comparison).ti.

8

((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.

9

(open adj label).ti,ab.

10

((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.

11

double blind procedure/

12

parallel group$1.ti,ab.

13

(crossover or cross over).ti,ab.

14

((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant$1)).ti,ab.

15

(assigned or allocated).ti,ab.

16

(controlled adj7 (study or design or trial)).ti,ab.

17

(volunteer or volunteers).ti,ab.

18

human experiment/

19

trial.ti.

20

or/1‐19

21

exp breast/

22

exp breast disease/

23

(21 or 22) and exp neoplasm/

24

exp breast tumor/

25

exp breast cancer/

26

exp breast carcinoma/

27

(breast$ adj5 (neoplas$ or cancer$ or carcin$ or tumo$ or metasta$ or malig$)).ti,ab.

28

(or/23‐27) and (metasta$ or advance$).tw.

29

(((advance$ or metasta$) adj5 (cancer$ or carcinoma$ or neoplasm$ or tumour$ or tumor$)) and breast).tw.

30

(((stage 4 or stage IV or stage four) adj5 (cancer$ or carcinoma$ or neoplasm$ or tumour$ or tumor$)) and breast).tw.

31

28 or 29 or 30

32

exp partial mastectomy/ or exp subcutaneous mastectomy/ or exp mastectomy/ or exp segmental mastectomy/

33

mastectomy.tw.

34

exp breast surgery/

35

breast surgery.tw.

36

breast conserving surgery.tw.

37

breast sparing surgery.tw.

38

lumpectomy.tw.

39

partial breast resection.tw.

40

breast amputation.tw.

41

breast resection.tw.

42

or/32‐41

43

20 and 31 and 42

Appendix 5. WHO ICTRP search strategy

Basic searches:

1. Breast surgery for metastatic breast cancer

2. Metastatic breast cancer AND breast surger*

3. Metastatic breast cancer AND mastectom*

4. Metastatic breast cancer AND lumpectom*

5. Advanced breast cancer AND breast surger*

6. Advanced breast cancer AND mastectom*

7. Advanced breast cancer AND lumpectom*

Advanced searches:

1. Title: breast surgery for metastatic breast cancer

Recruitment: ALL

2. Condition: metastatic breast cancer

Intervention: mastectom* OR lumpectom* OR breast surger* OR breast conserving surger*

Recruitment: ALL

3. Condition: advanced breast cancer

Intervention: mastectom* OR lumpectom* OR breast surger* OR breast conserving surger*

Recruitment: ALL

Appendix 6. ClinicalTrials.gov search strategy

Basic searches:

1. Breast surgery for metastatic breast cancer

2. Metastatic breast cancer AND breast surgery

3. Metastatic breast cancer AND mastectomy

4. Metastatic breast cancer AND lumpectomy

5. Advanced breast cancer AND breast surgery

6. Advanced breast cancer AND mastectomy

7. Advanced breast cancer AND lumpectomy

Advanced searches:

1. Title: breast surgery for metastatic breast cancer

Recruitment: All studies

Study results: All studies

Study type: All studies

Gender: All studies

2. Condition: metastatic breast cancer

Intervention: mastectomy OR lumpectomy OR breast surgery OR breast conserving surgery

Recruitment: All studies

Study results: All studies

Study type: All studies

Gender: All studies

3. Condition: advanced breast cancer

Intervention: mastectomy OR lumpectomy OR breast surgery OR breast conserving surgery

Recruitment: All studies

Study results: All studies

Study type: All studies

Gender: All studies

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figures and Tables -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Forest plot of comparison: 1 Systemic treatment plus surgery versus systemic treatment, outcome: 1.1 Overall survival.
Figures and Tables -
Figure 3

Forest plot of comparison: 1 Systemic treatment plus surgery versus systemic treatment, outcome: 1.1 Overall survival.

Forest plot of comparison: 1 Systemic treatment plus surgery versus systemic treatment, outcome: 1.5 Progression‐free survival.
Figures and Tables -
Figure 4

Forest plot of comparison: 1 Systemic treatment plus surgery versus systemic treatment, outcome: 1.5 Progression‐free survival.

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 1 Overall survival.
Figures and Tables -
Analysis 1.1

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 1 Overall survival.

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 2 Overall survival ‐ HER2 status.
Figures and Tables -
Analysis 1.2

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 2 Overall survival ‐ HER2 status.

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 3 Overall survival ‐ ER status.
Figures and Tables -
Analysis 1.3

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 3 Overall survival ‐ ER status.

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 4 Overall survival ‐ only bone metastasis.
Figures and Tables -
Analysis 1.4

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 4 Overall survival ‐ only bone metastasis.

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 5 Progression‐free survival.
Figures and Tables -
Analysis 1.5

Comparison 1 Systemic treatment plus surgery versus systemic treatment, Outcome 5 Progression‐free survival.

Summary of findings for the main comparison. Breast surgery plus systemic treatment compared to systemic treatment for metastatic breast cancer

Breast surgery plus systemic treatment compared to systemic treatment for metastatic breast cancer

Patient or population: metastatic breast cancer
Setting: inpatients and outpatients
Intervention: breast surgery plus systemic treatment
Comparison: systemic treatment

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with systemic treatment

Risk with breast surgery plus systemic treatment

Overall survival at 2 years

Follow‐up: range 23 months to 40 months

Study population

HR 0.83
(0.53 to 1.31)

624
(2 RCTs)

⊕⊝⊝⊝
VERY LOW 1 2 3

The estimates for the control group are based upon an average of the estimates from Badwe 2015 and Soran 2016.

511 per 1000

448 per 1000
(318 to 608)

Quality of life

Not reported

Not reported

Local PFS at 2 years

Follow‐up: range 23 months to 40 months

Study population

HR 0.22
(0.08 to 0.57)

607
(2 RCTs)

⊕⊕⊝⊝
LOW 2 4

The estimates for the control group are based upon an average of the estimates from Badwe 2015 and Soran 2016.

500 per 1000

141 per 1000
(54 to 326)

Distant PFS at 2 years

Follow‐up: 23 months

Study population

HR 1.42
(1.08 to 1.86)

350
(1 RCT)

⊕⊕⊕⊝
MODERATE 5

The estimates for the control group are based upon the estimates from Badwe 2015.

548 per 1000

676 per 1000
(576 to 772)

Breast cancer‐specific survival

Not reported

Not reported

Toxicity from local therapy

Follow‐up: 40 months

Study population

RR 0.99
(0.14 to 6.90)

274
(1 RCT)

⊕⊕⊝⊝
LOW 1 6

The estimates for the control group are based upon the estimates from Soran 2016.

15 per 1000

15 per 1000
(2 to 101)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

1In Soran 2016, trial random sequence generation and allocation concealment were unclear. Downgraded one level.
2Statistical or clinical heterogeneity, or both. Downgraded one level.
3Wide 95% CI (0.53 to 1.31) including the null effect. Downgraded one level.
4In Soran 2016, trial random sequence generation and allocation concealment were unclear. Outcome assessors were not blinded, and this is a subjective outcome. Downgraded one level.
5Outcome assessors were not blinded, and this is a subjective outcome. Downgraded one level.
6Very wide 95% CI (0.14 to 6.9). Downgraded one level.

Figures and Tables -
Summary of findings for the main comparison. Breast surgery plus systemic treatment compared to systemic treatment for metastatic breast cancer
Table 1. Overall survival ‐ subgroup analyses

Overall survival subgroup analysis

Number of studies

N

HR

Lower CI

Upper CI

P value

HER2‐positive

2

192

0.90

0.60

1.35

NS

HER2‐negative

2

421

0.85

0.67

1.08

NS

ER positive

2

426

0.79

0.61

1.03

NS

ER negative

2

200

1.01

0.73

1.40

NS

Bone‐only metastasis

2

226

0.91

0.49

1.69

NS

CI: confidence interval
ER: oestrogen receptor
HR: hazard ratio
NS: not significant

Figures and Tables -
Table 1. Overall survival ‐ subgroup analyses
Comparison 1. Systemic treatment plus surgery versus systemic treatment

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Overall survival Show forest plot

2

624

Hazard Ratio (Random, 95% CI)

0.83 [0.53, 1.31]

2 Overall survival ‐ HER2 status Show forest plot

2

Hazard Ratio (Random, 95% CI)

Subtotals only

2.1 HER2‐positive

2

192

Hazard Ratio (Random, 95% CI)

0.85 [0.48, 1.50]

2.2 HER2‐negative

2

421

Hazard Ratio (Random, 95% CI)

0.84 [0.50, 1.40]

3 Overall survival ‐ ER status Show forest plot

2

Hazard Ratio (Random, 95% CI)

Subtotals only

3.1 ER‐positive

2

426

Hazard Ratio (Random, 95% CI)

0.83 [0.48, 1.42]

3.2 ER‐negative

2

200

Hazard Ratio (Random, 95% CI)

1.04 [0.70, 1.55]

4 Overall survival ‐ only bone metastasis Show forest plot

2

226

Hazard Ratio (Random, 95% CI)

0.91 [0.49, 1.69]

5 Progression‐free survival Show forest plot

2

Hazard Ratio (Random, 95% CI)

Subtotals only

5.1 Local progression‐free survival

2

Hazard Ratio (Random, 95% CI)

0.22 [0.08, 0.57]

5.2 Distant progression‐free survival

1

Hazard Ratio (Random, 95% CI)

1.42 [1.08, 1.86]

Figures and Tables -
Comparison 1. Systemic treatment plus surgery versus systemic treatment